Functional impairment of infiltrating T cells in human colorectal cancer

OncoImmunology

Volumn 5, Issue 11, 2016, Pages

  Taylor, Edward S ^a   McCall, John L ^a   Girardin, Adam ^a   Munro, Fran M ^a   Black, Michael A ^a   Kemp, Roslyn A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Colorectal cancer; exhaustion; IL 2; proliferation; T cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 2; KI 67 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CELL ISOLATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SELECTION; COLORECTAL CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FUNCTIONAL DISEASE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 84994106550     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1234573     Document Type: Article

References (42)

1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2016:1-9; PMID:26187505; doi:10.1136/gutjnl-2015-310912
2. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; doi:10.1016/j.immuni.2013.10.003
3. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T-cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; doi:10.1056/NEJMoa051424
4. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; doi:10.1002/path.4287
5. Amin M, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin Inv Drugs 2015; 24:329-44; doi:10.1517/13543784.2015.985376
6. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003; 3:331-41; PMID:12669023; doi:10.1038/nri1057
7. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61-73; PMID:23890064; doi:10.1016/j.immuni.2013.07.005
8. Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, Taieb J. Colorectal cancer and immunity:what we know and perspectives. World J Gastroenterol 2014; 20:3738-50; PMID:24833840; doi:10.3748/wjg.v20.i14.3738
9. Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeser RA, et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 2015; PMID:26719303; doi:10.1136/gutjnl-2015-310016
10. Dunne MR, Ryan C, Nolan B, Tosetto M, Geraghty R, Winter DC, O'Connell PR, Hyland JM, Doherty GA, Sheahan K, et al. Enrichment of inflammatory IL-17 and TNF-α secreting CD4(+) T-cells within colorectal tumors despite the presence of elevated CD39(+) T regulatory cells and increased expression of the immune checkpoint molecule, PD-1. Front Oncol 2016; 6:50; PMID:27014625; doi:10.3389/fonc.2016.00050
11. Girardin A, McCall J, Black MA, Edwards F, Phillips V, Taylor ES, Reeve AE, Kemp RA. Inflammatory and regulatory T-cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. Int J Cancer 2013; 132:1842-50; PMID:23002055; doi:10.1002/ijc.27855
12. Ling L, Lin Y, Zheng W, Hong S, Tang X, Zhao P, Li M, Ni J, Li C, Wang L, et al. Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci Rep 2016; 6:20358; PMID:26837580; doi:10.1038/srep20358
13. Ling L, Zhao P, Yan G, Chen M, Zhang T, Wang L, Jiang Y. The frequency of Th17 and Th22 cells in patients with colorectal cancer at pre-operation and post-operation. Immunol Invest 2015; 44:56-69; PMID:25026244; doi:10.3109/08820139.2014.936445
14. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40:785-800; PMID:24816404; doi:10.1016/j.immuni.2014.03.013
15. Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest 2015; 125:1-13; PMID:25654544; doi:10.1172/JCI81442
16. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection:implications for vaccine design. Nat Rev Immunol 2008; 8:247-58; PMID:18323851; doi:10.1038/nri2274
17. Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, Yoshikawa H, Kaneko F, Suzuki T, Suzuki N. Excessive CD4+ T-cells co-expressing interleukin-17 and interferon-γ in patients with Behçet's disease. Clin Exp Immunol 2012; 168:68-74; PMID:22385240; doi:10.1111/j.1365-2249.2011.04543.x
18. + T-cells by regulatory T-cells is associated with progression of human colorectal cancer. Gut 2012; 61:1163-71; PMID:22207629; doi:10.1136/gutjnl-2011-300970
19. Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Science Transl Med 2014; 6:228-37; doi:10.1126/scitranslmed.3007240
20. + T-cells associated with dysfunction of cell-mediated immunity after colorectal cancer operation. Yonago Acta Medica 2012; 55:1-9; PMID:24031134
21. Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. The immune microenvironment of human tumors:General significance and clinical impact. Cancer Microenviron 2013; 6:117-22; PMID:23108700; doi:10.1007/s12307-012-0124-9
22. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; doi:10.1038/nature13988
23. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer Is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2014; 5:43-51; PMID:25358689; doi:10.1158/2159-8290.CD-14-0863
24. Wu X, Zhang H, Xing Q, Cui J, Li J, Li Y, Tan Y, Wang S. PD-1(+) CD8(+) T-cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Brit J Cancer 2014; 111:1391-9; PMID:25093496; doi:10.1038/bjc.2014.416
25. Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia 2014; 16:31-42; PMID:24563618; doi:10.1593/neo.131568
26. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56; PMID:25534622; doi:10.1038/nri3790
27. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; doi:10.1056/NEJMoa1500596
28. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016; 29:1104-12; PMID:27198569; doi:10.1038/modpathol.2016.95
29. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016; 44:698-711; PMID:26982367; doi:10.1016/j.immuni.2016.02.025
30. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T-cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012; 10:156; PMID:22862954; doi:10.1186/1479-5876-10-156
31. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T-cells. Nature 2006; 441:890-3; PMID:16778891; doi:10.1038/nature04790
32. Wu CY, Kirman JR, Rotte MJ, Davey DF, Perfetto SP, Rhee EG, Freidag BL, Hill BJ, Douek DC, Seder RA. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 2002; 3:852-8; PMID:12172546; doi:10.1038/ni832
33. Itoh Y, Germain RN. Single cell analysis reveals regulated hierarchical T-cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T-cells. J Exp Med 1997; 186:757-66; PMID:9271591; doi:10.1084/jem.186.5.757
34. Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T-cell receptor sequences that differ from the T-cells in adjacent mucosal tissue. Cancer Immunol Immun 2013; PMID:23771160; 62:1453-61; doi:10.1007/s00262-013-1446-2
35. + suppressive T-cells in colorectal cancer tissue. Gut 2009; 58:520-9; PMID:19022917; doi:10.1136/gut.2008.158824
36. O'Toole A, Michielsen AJ, Nolan B, Tosetto M, Sheahan K, Mulcahy HE, Winter DC, Hyland JM, O'Connell PR, Fennelly D, et al. Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. Brit J Cancer 2014; 111:927-32; PMID:25058349; doi:10.1038/bjc.2014.367
37. Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm 2014; 2014:623759; doi:10.1155/2014/623759
38. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115:5385-92; PMID:20395418; doi:10.1182/blood-2009-10-246660
39. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; doi:10.1158/0008-5472.CAN-10-2907
40. Das SN, Khanna NN, Khanna S. In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis. Cancer Invest 1986; 4:207-16; PMID:3719410; doi:10.3109/07357908609018450
41. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T-cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480-90; PMID:19543225; doi:10.1038/nri2580
42. + regulatory T-cells. Mucosal Immunol 2014; 7:428-39; PMID:24064667; doi:10.1038/mi.2013.62